Extended indication Metastatic breast cancer with gBRCA1/2 mutations - monotherapy in patients who have previously recei
Therapeutic value No judgement

Product

Active substance Olaparib
Domain Oncology and Hematology
Main indication Breast cancer
Extended indication Metastatic breast cancer with gBRCA1/2 mutations - monotherapy in patients who have previously received treatment with anthracycline and taxane and are suitable for single-agent chemotherapy.
Proprietary name Lynparza
Manufacturer AstraZeneca
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Expected Registration 2019
Orphan drug No
Additional remarks Dit is een indicatie-uitbreiding.

Therapeutic value

Current treatment options Concurrentie van alle parp-remmers.
Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

< 549

Market share is generally not included unless otherwise stated.

References NKR
Additional remarks NKR 2015: 5486 diagnoses mammacarcinoom stadium 2. 5-10% van borstkankers wordt veroorzakt door BRCA mutaties.

Expected cost per patient per year

Additional remarks €11,78 voor 50mg capsule.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.